Trial Profile
A Randomized Phase II Study of Afinitor (RAD001) vs. Sutent (Sunitinib) in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma (ASPEN)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Feb 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms ASPEN
- 16 Feb 2021 Results published in the Clinical Cancer Research
- 11 May 2016 Time frame for primary endpoint has been changed from 6,12,24 months to 24 months.
- 12 Jan 2016 Results published in the Lancet Oncology